Sangamo Therapeutics

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Retrieved on: 
星期四, 五月 9, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, STAC, FDA, CTA, Haemophilia, Enzyme replacement therapy, Kite, Investment, Nav1.7, Fabry disease, Poster, Disease, ERT, Sigma-Aldrich, STAAR, Health care, MAA, Partnership, Sangamo Therapeutics, MINT, AAV, Ligand Pharmaceuticals, IND, Tauopathy, Novartis, DNA, Patient, Pivotal, DSM-IV codes, EMA, Prion, BBB, Genome, BLA, MHRA, Manuscript, BioRxiv, Capsid, Modularity, Biogen, Therapy, Food and Drug Administration, European Medicines Agency, Gene, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
  • “We are pleased with the progress being made in business development discussions across our portfolio, including our Fabry disease program.
  • An IND submission is expected in the fourth quarter of 2024.
  • Revenues for the first quarter ended March 31, 2024 were $0.5 million, compared to $158.0 million for the same period in 2023.

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

Retrieved on: 
星期四, 五月 9, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Health Technology, Risk, Poster, Disease, LNP, Cell, Sangamo Therapeutics, MINT, Publication, AAV, DNA, Patient, Gene, Society, Genome, Manuscript, BioRxiv, Modularity, Annual general meeting, Therapy, Vaccine

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.
  • Building on Sangamo’s deep expertise in protein-DNA interactions derived from its zinc finger platform, the Modular Integrase (MINT) platform is a versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome to potentially treat – with a single medicine – patients who have unique mutations in the same gene.
  • “Precisely integrating large DNA constructs into desirable chromosomal sites has traditionally been challenging for the field.
  • We are excited that our new MINT platform potentially addresses this long-standing problem and would allow us to pursue new indications by inserting or replacing entire genes,” said Greg Davis, Ph.D., Head of Technology at Sangamo.

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast

Retrieved on: 
星期四, 五月 2, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, Therapy, Sangamo Therapeutics

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024.
  • The company will hold a conference call at 4:30 p.m. Eastern on Thursday, May 9, which will be open to the public.
  • During the conference call, the company will review its financial results and provide business updates.
  • The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events .

Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

Retrieved on: 
星期三, 四月 10, 2024
University, Ipsen, Obesity, Novartis, IPO, Therapy, Pfizer, CML, Head, Biology, Biogen, Sangamo Therapeutics, Growth, Pharmaceutical industry

FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.

Key Points: 
  • FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.
  • “We are excited to welcome Melita to the Terns leadership team at a critical stage of growth at the company,” said Amy Burroughs, chief executive officer of Terns.
  • Most recently, she served as chief business officer at Structure Therapeutics, where she was responsible for the company’s business strategy, partnering initiatives, commercial planning, corporate branding and communications.
  • Previously, Ms. Jung served as senior vice president and head of business development at Sangamo Therapeutics, a genomic medicines company.

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
星期一, 四月 22, 2024
Research, Infectious Diseases, Neurology, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, STAC, Neuron, Central nervous system disease, Dravet syndrome, Central nervous system, MD, Sangamo Therapeutics, Cell, AAV, Tauopathy, CNS, Engineering, DNA, Charcot–Marie–Tooth disease, Patient, Gene, Society, DSM-IV codes, Prion, Angelman syndrome, ALS, Genome, Capsid, Therapy, Powder metallurgy

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT Annual Meeting being held May 7-11, 2024, in-person in Baltimore, MD and in a virtual format.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT Annual Meeting being held May 7-11, 2024, in-person in Baltimore, MD and in a virtual format.
  • Presentations will focus on the progression of Sangamo’s neurology-focused pre-clinical pipeline, including data supporting innovations in zinc finger epigenetic regulation, advances in AAV capsid engineering, and discovery of next-generation integrase technology.
  • These data will showcase a novel AAV capsid, STAC-BBB, that exhibited robust and widespread central nervous system transduction in cynomolgus macaques after intravenous delivery, as well as another novel AAV capsid, STAC-150, engineered to accelerate the discovery of potent and highly specific epigenetic regulators.
  • Sangamo will also present additional data from its AAV capsid engineering platform SIFTER and its efforts for integrase evolution and utilization.

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

Retrieved on: 
星期五, 三月 22, 2024
Health, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, AAV, Sangamo Therapeutics, Form, Telephone, Sale, Attention, Security (finance), Prospectus, Form S-3, Capital market, Cantor, Broadridge Financial Solutions, Therapy, Barclays

The combined offering price of each share of common stock and accompanying warrant is $0.84, priced at-the-market under Nasdaq rules.

Key Points: 
  • The combined offering price of each share of common stock and accompanying warrant is $0.84, priced at-the-market under Nasdaq rules.
  • The combined offering price of each pre-funded warrant and accompanying warrant is $0.83.
  • The gross proceeds to Sangamo from the offering, before deducting the placement agents’ fees and other offering expenses, are expected to be approximately $24.0 million.
  • The offering is expected to close on or about March 26, 2024, subject to customary closing conditions.

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期三, 三月 13, 2024
Health, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, STAC, Gene, Orphan drug, ALTA, Haemophilia A, BBB, Patient, Health care, Quality of life, IND, Male, ERT, Investment, Therapy, Fabry disease, Plasma, Kite, Gene expression, Partnership, Central nervous system, Novartis, CNS, Pivotal, EMA, Prion, STAAR, Enzyme replacement therapy, Biogen, Tauopathy, Workforce, BLA, AAV, Sanofi, Research, DRG, Neuron, Hematology, FDA, DSM-IV codes, Brain, Sangamo Therapeutics, MAA, Haemophilia, CTA, Mouse, Female, Traffic barrier, Sodium, MHRA, Excipient, Society, Spinal cord, Toxicology, Sigma-Aldrich, Liver, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.
  • “In 2023, Sangamo announced the prioritization of its pipeline programs that support our focus as a neurology-focused genomic medicine company,” said Sandy Macrae, Chief Executive Officer of Sangamo.
  • STAC-BBB was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues.
  • Revenues for the fourth quarter ended December 31, 2023 were $2.0 million, compared to $27.2 million for the same period in 2022.

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

Retrieved on: 
星期三, 三月 13, 2024
Research, Neurology, Genetics, Clinical Trials, Health, Pharmaceutical, General Health, Other Science, Science, STAC, AAV, Sangamo Therapeutics, Gene, Brain, Capsid, Gene expression, ALS, BBB, Central nervous system, Novartis, CNS, CTA, DRG, Traffic barrier, Prion, NHP, Tropism, IND, Nav1.7, Neuron, Biogen, Tauopathy, Excipient, Therapy, DSM-IV codes, Spinal cord, Liver, Animal, Vaccine

Sangamo is exploring avenues to resume development of these programs internally, subject to receipt of adequate funding, or with new potential collaborators.

Key Points: 
  • Sangamo is exploring avenues to resume development of these programs internally, subject to receipt of adequate funding, or with new potential collaborators.
  • In NHP studies when administered intravenously at clinically relevant doses, STAC-BBB demonstrated its potential to be a leading neurotropic capsid.
  • Exhibited 700-fold higher transgene expression in neurons compared to the benchmark capsid AAV9 and outperformed all other known published neurotropic capsid variants evaluated in the study.
  • STAC-BBB was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues.

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

Retrieved on: 
星期二, 三月 12, 2024
Other Health, Research, Sports, Pharmaceutical, Genetics, Clinical Trials, Science, Biotechnology, Neurology, Sailing, FDA, Health, Sangamo Therapeutics, Therapy

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before the market opens on Wednesday, March 13, 2024.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before the market opens on Wednesday, March 13, 2024.
  • The Company will hold a conference call at 4:30 p.m. Eastern on Wednesday, March 13, which will be open to the public.
  • During the conference call, the company will review its financial results and provide business updates.
  • The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events.

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

Retrieved on: 
星期二, 三月 12, 2024
CONNECT, Internal medicine, University, Growth, Biotechnology, Novo Nordisk, Hematology, Science, AML, Monroe Dunaway Anderson, Executive, Patient, SAN, Novartis, FLT3, Head, Drug, Therapy, Drug development, Sangamo Therapeutics, Molecular Partners, MorphoSys, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D.
  • as Executive Vice President and Chief Medical Officer.
  • Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology.
  • Prior to joining Rigel, Dr. Rojkjaer held several leadership positions in clinical development and medical affairs at biotechnology and global pharmaceutical companies, having most recently served as Chief Medical Officer of Sangamo Therapeutics.